HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Peptide Receptors (Peptide Receptor)

Subscribe to New Research on Peptide Receptors

Cell surface receptors that bind peptide messengers with high affinity and regulate intracellular signals which influence the behavior of cells.

Also Known As:

Peptide Receptor; Receptors, Peptide; Peptide Hormone Receptor; Receptors, Peptide Hormones; Receptors, Peptides; Hormone Receptor, Peptide; Hormone Receptors, Peptide; Hormones Receptors, Peptide; Peptide Hormones Receptors; Peptides Receptors; Receptor, Peptide; Receptor, Peptide Hormone; Receptors, Peptide Hormone; Peptide Hormone Receptors

Networked: 579 relevant articles (26 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Membrane Proteins: 5300
    - Cell Surface Receptors: 753
      - Peptide Receptors: 579
        Angiotensin Receptors: 1517
        Endothelin Receptors: 1145
        Growth Factor Receptors: 766
        Thrombin Receptors: 257
        Formyl Peptide Receptors: 205
        Calcitonin Receptors: 128
        enterotoxin receptor: 109
        Neuropeptide Receptors: 71
        Atrial Natriuretic Factor Receptors: 56
        anthrax toxin receptors: 51
        anti-Mullerian hormone receptor: 35
        Adrenomedullin Receptors: 26
        plasmin receptor: 26
        relaxin receptors: 20
        Parathyroid Hormone Receptors: 15
        Albumin Receptors: 12
        alpha-latrotoxin receptor: 8
        KDEL receptor: 6
        hemopexin receptor: 5
        signal sequence receptor: 5
        fibrin receptor: 4
        placental lactogen receptor: 4
        ceruloplasmin receptor: 2
        chalone receptor: 2
        Gastrointestinal Hormone Receptors: 2
        intrinsic factor receptor: 2
        signal peptide receptor: 2
        kininogen receptor: 1
        Pituitary Hormone-Regulating Hormone Receptors: 1
        sarafotoxin receptor: 1
        SchistoFLRFamide receptor: 1
        trefoil factor receptor: 1
        annexin V receptor
        arginyl-glycyl-aspartic acid directed cell adhesion receptor
        C elegans B0457.1 protein
        C elegans VRFamide receptor 1
        cyclophilin B receptor
        Drosophila boss protein
        Drosophila CG6986 protein
        Drosophila DMSR-1 protein
        Drosophila DMSR-2 protein
        Drosophila ecdysis-triggering hormone receptor
        ferriexochelin receptor
        fibrin-fibrinogen degradation products receptor
        glutathione receptor
        HDEL receptor
        human alpha-fetoprotein receptor
        human annexin II receptor
        human annexin-A1 receptor
        human EMR3 protein
        human GPR15 protein
        human KDELR1 protein
        human LPHN1 protein
        human LPHN3 protein
        human neutrophil-activating peptide 2 receptor
        human PROKR2 protein
        human RXFP1 protein
        human RXFP4 protein
        Hydra head activator receptor
        Invertebrate Peptide Receptors
        mast cell degranulating peptide receptor
        monitor peptide receptor
        mouse alpha-fetoprotein receptor
        mouse ANTXR1 protein
        mouse ANTXR2 protein
        mouse Fpr-rs6 protein
        mouse Fpr-rs7 protein
        mouse Lphn1 protein
        mouse Prokr2 protein
        Pancreatic Hormone Receptors
        PHI peptide receptor
        Pituitary Hormone Receptors
        Plasmodium ERD2 protein
        prepro-THR (160-169) receptor
        proline-rich polypeptide receptor
        rat alpha-fetoprotein receptor
        rat ATPase beta-subunit
        rat Lgr7 protein
        rat Nogo receptor
        rat prokineticin receptor 2
        S cerevisiae ERD2 protein
        Streptococcus Plr protein
        thymopoietin receptor
        trypsin-modulating oostatic factor receptor
        vasoactive intestinal contractor receptor
        Yarrowia lipolytica SRP101 protein
        zebrafish RXFP3 protein

Experts

1.	Reubi, Jean Claude: 28 articles (06/2015 - 05/2003)
2.	Krenning, Eric P: 21 articles (02/2016 - 12/2002)
3.	Waser, Beatrice: 18 articles (06/2015 - 07/2002)
4.	de Jong, Marion: 17 articles (05/2015 - 04/2003)
5.	Kwekkeboom, Dik J: 15 articles (02/2016 - 04/2003)
6.	Baum, Richard P: 15 articles (07/2015 - 07/2006)
7.	Makis, William: 13 articles (01/2016 - 02/2015)
8.	McEwan, Alexander J B: 13 articles (01/2016 - 02/2015)
9.	McCann, Karey: 13 articles (01/2016 - 02/2015)
10.	Bodei, Lisa: 11 articles (12/2015 - 03/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2010 - "Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. " 01/01/2013 - "Peptide receptor radionuclide therapy (PRRT) has been shown to be effective against this tumor manifestation. " 12/01/2002 - "Peptide receptor radionuclide therapy with (111)In-DTPA(0)-octreotide is effective in SS-R-positive tumors. " 12/14/2009 - "We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. " 01/01/2005 - "Peptide receptor radionuclide therapy (PRRT) holds great promise for the future regarding the treatment of various cancers. "
2.	Neuroendocrine Tumors (Neuroendocrine Tumor) 08/01/2011 - "Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival. " 11/01/2012 - "Peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is an efficient new treatment option in patients with neuroendocrine tumors (NETs), with low risk of toxicity. " 02/01/2015 - "Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. " 07/01/2014 - "Peptide receptor radionuclide therapy (PRRT) is a promising treatment option for patients with metastatic or unresectable pulmonary neuroendocrine tumors. " 11/01/2014 - "Standardization would help define the characteristics of response, including progression-free survival; provide homogeneous phase II and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for approval by the regulatory authorities. "
3.	Carcinoma (Carcinomatosis) 08/01/2015 - "Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery." 10/01/2013 - "First experience using peptide receptor radionuclide therapy in a patient with urothelial carcinoma." 02/01/2007 - "These studies revealed the presence of the 3 known natriuretic peptide receptors A, B and C in PC-3 and DU-145 human prostate carcinoma cells (American Type Culture Collection, Manassas, Virginia) as well as in tissue samples of human prostate cancer. " 12/01/2014 - "Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation." 04/01/1986 - "We have identified a factor constitutively produced by the human bladder carcinoma cell line 5637, which has the following capacities: to induce the differentiation of the human promyelocytic leukemic cell line HL-60; to induce the expression of chemotactic peptide receptors in leukemic cells as well as in normal peripheral blood granulocytes; to function as a chemoattractant for neutrophils as well as, under certain conditions, inhibiting their migration; to support the growth of eosinophil and granulocyte/macrophage progenitors, which is maximal when scored at day 14; and to support the growth of human mixed pluripotent progenitors and erythroid bursts from normal human bone marrow. "
4.	Neoplasm Metastasis (Metastasis) 04/15/2015 - "Peptide receptor radionuclide therapy is a promising palliative procedure for patients with hepatic and/or extrahepatic metastases. " 01/01/2014 - "Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? " 01/01/2013 - "Bone metastases (BM) of gastroenteropancreatic neuroendocrine tumours (GEP-NET) can be effectively controlled by peptide receptor radionuclide therapy (PRRT). " 10/01/2012 - "A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). " 02/01/2012 - "Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. "
5.	Cardiomegaly (Heart Hypertrophy) 04/01/2002 - "Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice." 05/31/2011 - "Caveolae, microdomains in the plasma membrane that contain caveolin proteins and natriuretic peptide receptors, have been implicated in cardiac hypertrophy and natriuretic peptide localization. " 05/06/2008 - "Mice lacking guanylyl cyclase-A (GC-A), a natriuretic peptide receptor, have pressure-independent cardiac hypertrophy. " 05/01/2003 - "Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A." 01/01/2000 - "Atrial natriuretic peptide (ANP) may function as an endogenous regulator of cardiac hypertrophy, because the natriuretic peptide receptor has been found in the heart and because mice lacking its receptor have been shown to have a markedly elevated ventricular mass. "

Related Drugs and Biologics

1.	Somatostatin (Somatotropin Release-Inhibiting Factor)
2.	Somatostatin Receptors (Somatostatin Receptor)
3.	Radioisotopes (Radionuclides)
4.	Guanylate Cyclase (Guanylyl Cyclase)
5.	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
6.	(177lutetium-DOTA(O)Tyr3)octreotate
7.	Cyclic GMP
8.	orexins (orexin)
9.	DOTA-Tyr(3)- 90Y-octreotide
10.	Isotopes

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Hepatectomy
5.	Radioimmunotherapy